# Torus Biosystems

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/torus-biosystems

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.torus.bio
- Total disclosed funding: $25M
- Latest round: Series A (Apr 23, 2021)
- Investors on record: 1

## About

Based in Massachusetts, United States, and founded in 2019 by David R. Walt, David Zhang, Peng Yin, and Shawn Marcell (CEO), Torus Biosystems, Inc., is a biotechnical startup aiming to develop point-of-care molecular diagnostics for infectious disorders. The company was formed as the result of a spin-out from the Harvard Wyss Institute for Biologically Inspired Engineering. In April 2021, Torus Biosystems, Inc. raised USD 25 million in Series A funding led by new investor Northpond Ventures.

The company offers Torus Synestia™ System that takes urine, swabs, and blood samples and uses qPCR and microarray technologies to provide quick and comprehensive test results for major infectious diseases in a faster and more accurate format, resulting in better patient treatment. Torus Synestia™ System detects several infections from a single sample, eliminating the need for additional samples and tests. 

Torus Biosystems, Inc. intends to use the April 2021 funding to accelerate the commercialization of a first-in-class syndromic testing solution designed for point-of-care use in ambulatory care settings.

## Funding rounds

- Series A, Apr 23, 2021, $25M — Northpond Ventures

## Investors

- Northpond Ventures (https://capitalatlas.ai/funds/northpond-ventures) — Series A